Showing results (181-190 of 198) with videos related to
Sort By:
Pageof 20
Cold Spring Harbor Molecular Case Studies|June 17, 2018
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibJikui Guan, Susanne Fransson, Joachim Tetteh Siaw, et al.Proceedings of the National Academy of Sciences of the United States of America|August 5, 2020
Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cellsEvelyn Susanto, Ana Marin Navarro, Leilei Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the LiteratureAnnelot J M Meijer, Franciscus A Diepstraten, Marc Ansari, et al.Genome Medicine|January 28, 2024
Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesionsShenglin Mei, Adele M Alchahin, Ioanna Tsea, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Emergence of new ALK mutations at relapse of neuroblastomaGudrun Schleiermacher, Niloufar Javanmardi, Virginie Bernard, et al.Cancer Research Communications|August 23, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA AnalysisTorben Ek, Raghda R Ibrahim, Hartmut Vogt, et al.Drug Delivery|May 2, 2026
Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic reviewAmirhossein Masroor, Nienke Streefkerk, Martine Van Grotel, et al.Cancer Cell|March 14, 2018
Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory AxisTanmoy Mondal, Prasanna Kumar Juvvuna, Agnete Kirkeby, et al.Nature Genetics|April 9, 2021
Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma originPolina Kameneva, Artem V Artemov, Maria Eleni Kastriti, et al.The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.Pageof 20